These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29315307)

  • 1. Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial.
    Baxi SM; Vittinghoff E; Bacchetti P; Huang Y; Chillag K; Wiegand R; Anderson PL; Grant R; Greenblatt RM; Buchbinder S; Gandhi M; Liu AY
    PLoS One; 2018; 13(1):e0190118. PubMed ID: 29315307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
    Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
    AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
    Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
    Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research advances in HIV pre-exposure prophylaxis drug].
    Liu QZ; Yang X; Xu P; Qin QQ; Tang HL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Dec; 43(12):2036-2040. PubMed ID: 36572482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
    Abdool Karim SS; Baxter C; Abdool Karim Q
    Antivir Ther; 2022 Apr; 27(2):13596535211067589. PubMed ID: 35499171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance.
    Hsiao YY; Huang YC; Chang SY; Kuo CH; Chang SF; Lin YT; Luo YZ; Lee YL; Hung CC
    J Microbiol Immunol Infect; 2021 Aug; 54(4):755-757. PubMed ID: 33597075
    [No Abstract]   [Full Text] [Related]  

  • 8. Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Gvetadze RJ; Curlin ME; Leethochawalit M; Chiamwongpaet S; Cherdtrakulkiat T; Anekvorapong R; Leelawiwat W; Chantharojwong N; McNicholl JM; Paxton LA; Kittimunkong S; Choopanya K;
    Clin Infect Dis; 2014 Sep; 59(5):716-24. PubMed ID: 24829212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach.
    Seidman DL; Weber S; Cohan D
    J Int AIDS Soc; 2017 Mar; 20(Suppl 1):21295. PubMed ID: 28361503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where Were the Women? Gender Parity in Clinical Trials.
    Goldstein RH; Walensky RP
    N Engl J Med; 2019 Dec; 381(26):2491-2493. PubMed ID: 31665574
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK; Baeten JM
    Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
    Murewanhema G; Malisheni M; Takah NF
    Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program.
    Pintye J; Kinuthia J; Abuna F; Mugwanya K; Lagat H; Dettinger JC; Odinga D; Sila J; Anderson PL; John-Stewart G; Baeten JM
    Clin Infect Dis; 2020 Dec; 71(9):e509-e512. PubMed ID: 32109293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New PrEP formulation approved…but only for some.
    The Lancet Hiv
    Lancet HIV; 2019 Nov; 6(11):e723. PubMed ID: 31672278
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of Oral Fluid HIV Test Performance in an HIV Pre-Exposure Prophylaxis Trial in Bangkok, Thailand.
    Suntharasamai P; Martin M; Choopanya K; Vanichseni S; Sangkum U; Tararut P; Leelawiwat W; Anekvorapong R; Mock PA; Cherdtrakulkiat T; Leethochawalit M; Chiamwongpaet S; Gvetadze RJ; McNicholl JM; Paxton LA; Kittimunkong S; Curlin ME
    PLoS One; 2015; 10(12):e0145859. PubMed ID: 26717405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
    Velloza J; Heffron R
    Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.